174 related articles for article (PubMed ID: 2934022)
1. Evaluation of the in vitro bactericidal action of ciprofloxacin on cells of Escherichia coli in the logarithmic and stationary phases of growth.
Zeiler HJ
Antimicrob Agents Chemother; 1985 Oct; 28(4):524-7. PubMed ID: 2934022
[TBL] [Abstract][Full Text] [Related]
2. Influence of pH and human urine on the antibacterial activity of ciprofloxacin, norfloxacin and ofloxacin.
Zeiler HJ
Drugs Exp Clin Res; 1985; 11(5):335-8. PubMed ID: 2941261
[TBL] [Abstract][Full Text] [Related]
3. Assessment of the in vitro and in vivo activity of ciprofloxacin measured against current standards of therapy.
Zeiler HJ; Metzger KG; Schacht P; Grohe K
Drugs Exp Clin Res; 1985; 11(5):343-50. PubMed ID: 2941263
[TBL] [Abstract][Full Text] [Related]
4. Postantibiotic effect of ciprofloxacin compared with that of five other quinolones.
Minguez F; Ramos C; Barrientos S; Loscos A; Prieto J
Chemotherapy; 1991; 37(6):420-5. PubMed ID: 1760941
[TBL] [Abstract][Full Text] [Related]
5. Urinary bactericidal activity and pharmacokinetics of enoxacin versus norfloxacin and ciprofloxacin in healthy volunteers after a single oral dose.
Well M; Naber KG; Kinzig-Schippers M; Sörgel F
Int J Antimicrob Agents; 1998 Apr; 10(1):31-8. PubMed ID: 9624541
[TBL] [Abstract][Full Text] [Related]
6. Isolation and characterization of an Escherichia coli strain exhibiting partial tolerance to quinolones.
Wolfson JS; Hooper DC; Shih DJ; McHugh GL; Swartz MN
Antimicrob Agents Chemother; 1989 May; 33(5):705-9. PubMed ID: 2665642
[TBL] [Abstract][Full Text] [Related]
7. In vitro evaluation of A-56619 (difloxacin) and A-56620: new aryl-fluoroquinolones.
Stamm JM; Hanson CW; Chu DT; Bailer R; Vojtko C; Fernandes PB
Antimicrob Agents Chemother; 1986 Feb; 29(2):193-200. PubMed ID: 3087274
[TBL] [Abstract][Full Text] [Related]
8. Antagonism between bactericidal activities of 4-quinolones and coumarins gives insight into 4-quinolone killing mechanisms.
Howard BM; Pinney RJ; Smith JT
Microbios; 1994; 77(311):121-31. PubMed ID: 8152392
[TBL] [Abstract][Full Text] [Related]
9. Mutant prevention concentration of nalidixic acid, ciprofloxacin, clinafloxacin, levofloxacin, norfloxacin, ofloxacin, sparfloxacin or trovafloxacin for Escherichia coli under different growth conditions.
Linde HJ; Lehn N
J Antimicrob Chemother; 2004 Feb; 53(2):252-7. PubMed ID: 14688048
[TBL] [Abstract][Full Text] [Related]
10. Antimicrobial activity of ciprofloxacin against Pseudomonas aeruginosa, Escherichia coli, and Staphylococcus aureus determined by the killing curve method: antibiotic comparisons and synergistic interactions.
Chalkley LJ; Koornhof HJ
Antimicrob Agents Chemother; 1985 Aug; 28(2):331-42. PubMed ID: 2939797
[TBL] [Abstract][Full Text] [Related]
11. Bactericidal activity of ciprofloxacin upon Escherichia coli and Acinetobacter baumanni.
Zemelman R; Vejar C; Bello H; Domínguez M; González G
Rev Latinoam Microbiol; 1992; 34(4):245-8. PubMed ID: 1345113
[TBL] [Abstract][Full Text] [Related]
12. Impact of AAC(6')-Ib-cr in combination with chromosomal-mediated mechanisms on clinical quinolone resistance in Escherichia coli.
Machuca J; Ortiz M; Recacha E; Díaz-De-Alba P; Docobo-Perez F; Rodríguez-Martínez JM; Pascual Á
J Antimicrob Chemother; 2016 Nov; 71(11):3066-3071. PubMed ID: 27494906
[TBL] [Abstract][Full Text] [Related]
13. Effect of growth phase on the bactericidal action of chloramphenicol against Haemophilus influenzae type b and Escherichia coli K-1.
Feldman WE; Manning NS
Antimicrob Agents Chemother; 1983 Apr; 23(4):551-4. PubMed ID: 6344785
[TBL] [Abstract][Full Text] [Related]
14. Effect of quinolones against slowly growing bacteria.
Dalhoff A; Matutat S; Ullmann U
Chemotherapy; 1995; 41(2):92-9. PubMed ID: 7758362
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of ciprofloxacin in stationary-phase bacteria in vivo.
Zeiler HJ; Voigt WH
Am J Med; 1987 Apr; 82(4A):87-90. PubMed ID: 3107381
[TBL] [Abstract][Full Text] [Related]
16. Bactericidal activity of ciprofloxacin, norfloxacin and ofloxacin in serum and urine after oral administration to healthy volunteers.
Zeiler HJ; Beermann D; Wingender W; Förster D; Schacht P
Infection; 1988; 16 Suppl 1():S19-23. PubMed ID: 3286510
[TBL] [Abstract][Full Text] [Related]
17. Urine bactericidal activity against resistant Escherichia coli in an in vitro pharmacodynamic model simulating urine concentrations obtained after 2000/125 mg sustained-release co-amoxiclav and 400 mg norfloxacin administration.
Alou L; Aguilar L; Sevillano D; Giménez MJ; Cafini F; Valero E; Relaño MT; Prieto J
J Antimicrob Chemother; 2006 Apr; 57(4):714-9. PubMed ID: 16492718
[TBL] [Abstract][Full Text] [Related]
18. Conditions required for the bactericidal activity of fleroxacin and pefloxacin against Escherichia coli KL 16.
Lewin CS; Amyes SG
J Med Microbiol; 1990 Jun; 32(2):83-6. PubMed ID: 1693968
[TBL] [Abstract][Full Text] [Related]
19. Parameters of bacterial killing and regrowth kinetics and antimicrobial effect examined in terms of area under the concentration-time curve relationships: action of ciprofloxacin against Escherichia coli in an in vitro dynamic model.
Firsov AA; Vostrov SN; Shevchenko AA; Cornaglia G
Antimicrob Agents Chemother; 1997 Jun; 41(6):1281-7. PubMed ID: 9174184
[TBL] [Abstract][Full Text] [Related]
20. The in vitro and in vivo activity of ciprofloxacin.
Zeiler HJ; Grohe K
Eur J Clin Microbiol; 1984 Aug; 3(4):339-43. PubMed ID: 6237902
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
